PE20091782A1 - Derivados de sulfonamida sustituida - Google Patents

Derivados de sulfonamida sustituida

Info

Publication number
PE20091782A1
PE20091782A1 PE2009000496A PE2009000496A PE20091782A1 PE 20091782 A1 PE20091782 A1 PE 20091782A1 PE 2009000496 A PE2009000496 A PE 2009000496A PE 2009000496 A PE2009000496 A PE 2009000496A PE 20091782 A1 PE20091782 A1 PE 20091782A1
Authority
PE
Peru
Prior art keywords
piperidin
pyridin
aryl
alkyl
metoxy
Prior art date
Application number
PE2009000496A
Other languages
English (en)
Inventor
Stefan Oberboersch
Melanie Tracey Reich
Stefan Schunk
Michael Franz-Martin Engels
Ruth Jostock
Tieno Heiner Germann
Vry Jean Marie Victor De
Klaus Schiene
Sabine Maria Hees
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20091782A1 publication Critical patent/PE20091782A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE SULFONAMIDA DE FORMULA (I) DONDE m, o, p Y r SON CADA UNO DE 0 A 2; n ES 1 O 2; q ES DE 0 A 3; v Y w SON CADA UNO 0 O 1; An- ES ANION DE HALOGENURO; Q ES UN ENLACE SIMPLE, -O- O -CH2; R1 ES ARILO O HETEROARILO OPCIONALMENTE UNIDO MEDIANTE UN ALQUILENO(C1-C3); R2 ES H, ALQUILO(C1-C6), CICLOALQUILO(C3-C8), ENTRE OTROS; R3 ES H, ALQUILO(C1-C6), ARILO, ENTRE OTROS; R4 ES ARILO O HETEROARILO OPCIONALMENTE UNIDO MEDIANTE UN ALQUILENO(C1-C6); R5 Y R6 SON CADA UNO H, ALQUILO(C1-C6), CICLOALQUILO(C3-C8), ENTRE OTROS; R20 ES ALQUILO(C1-C6), CICLOPROPILO, ARILO, =O, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-((1-(4-METOXI-2,6-DIMETILFENILSULFONIL)PIPERIDIN-2-IL)-1-(4-(PIRIDIN-3-IL)-4-(2-PIRROLIDIN-1-IL)ETOXI)PIPERIDIN-1-IL)BUTAN-1-ONA, N-CICLOPROPILO-4-METOXI-2,6-DIMETIL-N-(2-(2-OXO-2-(4-(PIRIDIN-3-IL)-4-(2-(PIRROLIDIN-1-IL)ETOXI)PIPERIDIN-1-IL)ETOXI)ETIL)BENZOSULFONAMIDA, 4-METOXI-2,6-DIMETIL-N-(2-(2-OXO-2-(4-(PIRIDIN-3-IL)-4-(2-(PIRROLIDIN-1-IL)ETOXI)PIPERIDIN-1-IL)ETOXI)ETIL)-N-(PIRIDIN-3-ILMETIL)BENZOSULFONAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE BRADIQUININA 1 (B1R) SIENDO UTILES EN EL TRATAMIENTO DE DOLORES AGUDOS, MIGRANA
PE2009000496A 2008-04-08 2009-04-08 Derivados de sulfonamida sustituida PE20091782A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08006957 2008-04-08

Publications (1)

Publication Number Publication Date
PE20091782A1 true PE20091782A1 (es) 2009-11-15

Family

ID=39967424

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000496A PE20091782A1 (es) 2008-04-08 2009-04-08 Derivados de sulfonamida sustituida

Country Status (14)

Country Link
US (1) US8318769B2 (es)
EP (1) EP2262792A1 (es)
JP (1) JP2011517459A (es)
CN (1) CN102056919B (es)
AR (1) AR071363A1 (es)
AU (1) AU2009235634B8 (es)
CA (1) CA2720793A1 (es)
CL (1) CL2009000851A1 (es)
IL (1) IL208519A0 (es)
MX (1) MX2010011095A (es)
PE (1) PE20091782A1 (es)
RU (1) RU2503674C2 (es)
TW (1) TW200948801A (es)
WO (1) WO2009124733A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2066659T3 (da) * 2006-09-29 2013-12-09 Gruenenthal Gmbh Substitueret sulfonamid-derivat
US8404741B2 (en) * 2010-02-19 2013-03-26 Bristol-Myers Squibb Company Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase
HUP1000598A2 (en) 2010-11-05 2012-09-28 Richter Gedeon Nyrt Indole derivatives
JP2014159375A (ja) * 2011-06-15 2014-09-04 Takeda Chem Ind Ltd アゼパン化合物
CN107266378B (zh) * 2016-04-06 2020-08-21 南开大学 含有磺酰基结构三嗪酮衍生物及其制备方法和在杀虫、杀菌方面的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2743562B1 (fr) * 1996-01-11 1998-04-03 Sanofi Sa Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant
JP2002502379A (ja) * 1997-05-22 2002-01-22 ジー．ディー．サール アンド カンパニー ｐ３８キナーゼインヒビターとしての３（５）−ヘテロアリール置換ピラゾール
FR2822827B1 (fr) * 2001-03-28 2003-05-16 Sanofi Synthelabo Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant
EA008921B1 (ru) 2003-03-25 2007-08-31 Лаборатуар Фурнье С.А. Производные бензолсульфонамидов, способ их получения и их применение для лечения боли
EP1631542A1 (en) * 2003-04-10 2006-03-08 Amgen, Inc. Bicyclic compounds having bradykinin receptors affinity and pharmaceutical compositions thereof
WO2004092164A1 (en) 2003-04-10 2004-10-28 Amgen, Inc. Cyclic amine derivatives and their use in the treatment of inflammation-related disorders mediated by bradykinin
WO2007140383A2 (en) 2006-05-30 2007-12-06 Neurogen Corporation Spirocyclic sulfonamides and related compounds
DE102006039003A1 (de) * 2006-08-19 2008-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Verbindungen
WO2008024692A1 (en) 2006-08-23 2008-02-28 Neurogen Corporation N-oxide aryl sulfones and sulfoxides
DK2066659T3 (da) * 2006-09-29 2013-12-09 Gruenenthal Gmbh Substitueret sulfonamid-derivat
EP2086935A1 (de) * 2006-10-16 2009-08-12 Grünenthal GmbH Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren
DE102007020493A1 (de) * 2007-04-30 2008-11-06 Grünenthal GmbH Substituierte Amid-Derivate
DE102007020492A1 (de) * 2007-04-30 2008-11-06 Grünenthal GmbH Substituierte Sulfonamid-Derivate
TW200940528A (en) * 2008-03-05 2009-10-01 Gruenenthal Gmbh Substituted sulfonamide derivatives
TW200940523A (en) * 2008-03-17 2009-10-01 Gruenenthal Gmbh Substituted sulfonamide derivatives
PE20091731A1 (es) * 2008-04-08 2009-11-11 Gruenenthal Chemie Derivados de sulfonamida sustituida
BRPI1006128A2 (pt) * 2009-01-12 2016-11-01 Cagen Inc derivados de sulfonamida

Also Published As

Publication number Publication date
CL2009000851A1 (es) 2009-07-17
MX2010011095A (es) 2010-11-05
EP2262792A1 (de) 2010-12-22
CN102056919A (zh) 2011-05-11
AU2009235634A8 (en) 2013-05-23
RU2503674C2 (ru) 2014-01-10
AU2009235634B2 (en) 2013-04-18
IL208519A0 (en) 2010-12-30
TW200948801A (en) 2009-12-01
WO2009124733A8 (de) 2010-11-18
CA2720793A1 (en) 2009-10-15
AU2009235634A1 (en) 2009-10-15
US8318769B2 (en) 2012-11-27
WO2009124733A1 (de) 2009-10-15
US20090264400A1 (en) 2009-10-22
JP2011517459A (ja) 2011-06-09
AU2009235634B8 (en) 2013-05-23
CN102056919B (zh) 2014-03-12
AR071363A1 (es) 2010-06-16
RU2010145013A (ru) 2012-05-20

Similar Documents

Publication Publication Date Title
PE20210128A1 (es) Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
PE20120635A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20090773A1 (es) Derivados de morfolina pirimidina
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20142099A1 (es) Derivados de sulfonamida
PE20090237A1 (es) Derivados de sulfonamidas como inhibidores de los canales de sodio
PE20090621A1 (es) Pirrolidina-aril-eteres como antagonistas de receptores de nk3
PE20070528A1 (es) Compuestos heterociclicos como ligandos del receptor vaniloide del subtipo 1
EA200601785A1 (ru) Соединения и способы лечения дислипидемии
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20070642A1 (es) Compuestos derivados de pirazol como antagonistas del receptor de la progesterona
PE20091974A1 (es) Derivados de indazoles sustituidos con fenil o piridinilo
PE20141375A1 (es) Activadores de glucoquinasa
PE20170664A1 (es) Agonistas del receptor de apelina(apj) y usos de los mismos
NO20073663L (no) Tiazol-4-karboksamid-derivater som mGluR5 antagonister
NO20063470L (no) Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
PE20071245A1 (es) COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs)
ATE541839T1 (de) Pyrrolidiniumderivate als m3-muskarinische rezeptoren
ATE521606T1 (de) Quaternäre ammoniumsalze als m3-antagonisten
PE20091090A1 (es) Derivados de piperidina como agonistas de receptores muscarinicos
PE20090482A1 (es) Derivados heterociclicos como antagonistas del receptor ccr2
PE20090709A1 (es) Compuestos heterociclico de 5 miembros

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed